Prevention and treatment of synucleinopathic and amyloidogenic disease

Abstract

The invention provides improved agents and methods for treatment of diseases associated with synucleinopathic diseases, including Lewy bodies of alpha-synuclein in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the Lewy body. The methods are particularly useful prophylactic and therapeutic treatment of Parkinson's disease.

1 - 32 . (canceled) 
     
     
         33 . A method of obtaining a human antibody binding to an epitope within a defined segment of alpha synuclein comprising
 screening a DNA library obtained from B cells of a human for expression of antibodies binding to human alpha synuclein and   further screening the antibodies against deletion mutants of human alpha synuclein to identify an antibody binding within residues 1-10 or 110-130 of alpha synuclein.   
     
     
         34 . The method of  claim 33 , wherein the antibody binds within residues 1-10 of alpha synuclein. 
     
     
         35 . The method of  claim 33 , wherein the antibody binds within residues 110-130 of alpha synuclein. 
     
     
         36 . The method of  claim 33 , wherein the antibody binds within residues 118-126 of alpha synuclein. 
     
     
         37 . The method of  claim 33 , further comprising transforming nucleic acids encoding heavy and light of the antibody into a host cell and expressing the antibody. 
     
     
         38 . The method of  claim 37 , wherein the host cell is a CHO cell. 
     
     
         39 . The method of  claim 37 , further comprising purifying the antibody from a culture of the host cell. 
     
     
         40 . The method of  claim 37 , further comprising incorporating the antibody into a pharmaceutical composition.